Actuate Therapeutics Inc (ACTU) Stock Price, Quote & News

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric l...

Industry: Biotechnology

Sector: Healthcare

Phone: 817 887 8455

Website: actuatetherapeutics.com

Address:

1751 River Run, Suite 400, Fort Worth, United States

Mike_Rotsch Sep. 17 at 7:38 PM

$ACTU It doesn't like being under a dollar, does it?

0 · Reply

SamuraiX7 Sep. 11 at 11:01 PM

$ACTU $AEI $IMNN $SOAR $VSME VSME under big leg up coming

0 · Reply

Tonyto76 Sep. 11 at 3:07 PM

$ACTU WTF ? What's causing the dip ?

1 · Reply

prismmarketview Sep. 9 at 6:48 PM

$ACTU — preclinical data (with Northwestern + Mayo Clinic) shows elraglusib (GSK-3β inhibitor) enhances anticancer activity of zoldonrasib (RMC-9805, KRAS G12D) and daraxonrasib (RMC-6236, RAS(ON)) in mouse + human pancreatic cancer models, including FOLFIRINOX-resistant models. Different mechanisms = potential complementary strategy per company. No clinical trial timeline, enrollment plan, or regulatory pathway given. Additional data due at upcoming medical conferences. Preclinical only, doesn't establish safety/efficacy in patients. $ACTU #Biotech #Oncology https://prismmarketview.com/actuate-reports-preclinical-synergy-for-elraglusib-with-ras-inhibitors-in-pancreatic-cancer/

0 · Reply

MaximusRadius Sep. 5 at 1:15 AM

$ACTU https://finance.yahoo.com/markets/stocks/articles/know-actuate-therapeutics-inc-actu-160002662.html

0 · Reply

MaximusRadius Sep. 4 at 6:09 PM

$ACTU 1.36 looks like support level

0 · Reply

MaximusRadius Sep. 4 at 3:58 PM

$ACTU building up steam for a nice run

0 · Reply

stockoptrader Aug. 26 at 6:35 PM

$ACTU interesting…

1 · Reply

StupidestTrader Aug. 26 at 6:27 PM

$ACTU needs to break and hold 2.00 if can test of 2.25 next, needs to hold if can 2.70... if 2.00 can't hold, look for 1.50, if that fails, 1.25

1 · Reply

SmartMoneyTradez Aug. 26 at 2:08 PM

$ACTU impending news? They are getting volume

0 · Reply

Actuate Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 9, 2026, 5:00 PM EDT - 10 days ago

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 9, 2026, 7:00 AM EDT - 11 days ago

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

Actuate Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 5 weeks ago

Actuate Therapeutics Slides: Corporate presentation

2026-07-30T11:37:44.000Z - 7 weeks ago

Actuate Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 9, 2026, 7:45 AM EDT - 3 months ago

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Jun 1, 2026, 7:00 AM EDT - 3 months ago

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

2026-05-18T17:55:25.000Z - 4 months ago

Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital

May 14, 2026, 8:00 AM EDT - 4 months ago

Actuate Therapeutics Quarterly report: Q1 2026

2026-05-11T13:55:48.000Z - 4 months ago

Actuate Therapeutics receives FDA clearance for oral elraglusib study

May 11, 2026, 7:00 AM EDT - 4 months ago

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

May 9, 2026, 11:53 AM EDT - 4 months ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ATAI VVOS

May 6, 2026, 8:45 AM EDT - 4 months ago

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

May 6, 2026, 8:00 AM EDT - 4 months ago

Actuate Therapeutics Proxy statement: Proxy filing

2026-04-30T16:41:48.000Z - 4 months ago

Actuate Therapeutics management to meet with B. Riley

Apr 22, 2026, 7:23 AM EDT - 5 months ago

Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

Apr 14, 2026, 8:45 AM EDT - 5 months ago

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

2026-04-13T10:17:08.000Z - 5 months ago

Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Actuate Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Actuate Therapeutics Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Actuate Therapeutics Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 6 months ago

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

2026-03-09T12:57:35.000Z - 6 months ago

Actuate launches research initiative to combine elraglusib, RAS inhibitors

Mar 9, 2026, 8:45 AM EDT - 6 months ago

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Feb 24, 2026, 8:45 AM EST - 6 months ago

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-21T13:56:06.000Z - 8 months ago

Actuate Therapeutics announces plans to expand clinical pipeline

2026-01-12T13:51:27.000Z - 8 months ago

Actuate Therapeutics says Phase 2 study met primary endpoints

Jan 12, 2026, 8:45 AM EST - 8 months ago

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

2026-01-06T13:57:14.000Z - 8 months ago

Actuate announces results from Phase 1 portion of study of elraglusib

$Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers$

Jan 6, 2026, 8:45 AM EST - 8 months ago

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Dec 18, 2025, 8:45 AM EST - 9 months ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

2025-12-15T13:55:21.000Z - 9 months ago

Actuate Therapeutics announces publication of Phase II data for elraglusib

Nov 13, 2025, 7:00 AM EST - 10 months ago

Actuate Therapeutics Quarterly report: Q3 2025

2025-09-22T12:50:20.000Z - 12 months ago

Actuate announces corporate update on regulatory path for elraglusib

Sep 22, 2025, 8:45 AM EDT - 12 months ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

2025-09-10T12:45:51.000Z - 1 year ago

Actuate prices 2.14M shares at $7.00 in underwritten public offering

2025-09-10T12:35:09.000Z - 1 year ago

Actuate Therapeutics 2.142M share Secondary priced at $7.00

Sep 10, 2025, 8:31 AM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

2025-09-09T20:10:46.000Z - 1 year ago

Actuate Therapeutics announces common stock offering, no amount given

Sep 9, 2025, 4:07 PM EDT - 1 year ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

2025-09-02T20:35:57.000Z - 1 year ago

Actuate Therapeutics files $250M mixed securities shelf

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Registration statement: Registration filing

2025-08-26T08:45:11.000Z - 1 year ago

Actuate Therapeutics initiated with a Buy at B. Riley

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Quarterly report: Q2 2025

2025-08-06T12:51:12.000Z - 1 year ago

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

INCY

Aug 6, 2025, 8:45 AM EDT - 1 year ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

2025-07-25T20:05:36.000Z - 1 year ago

Actuate Therapeutics files to sell 1.33M shares of common stock for holders

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Registration statement: Registration filing

2025-07-17T12:55:30.000Z - 1 year ago

Actuate Therapeutics announces end of Phase 1 portion of elraglusib study

Jul 17, 2025, 8:45 AM EDT - 1 year ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

2025-06-24T13:26:49.000Z - 1 year ago

Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

Jun 24, 2025, 9:15 AM EDT - 1 year ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Jun 20, 2025, 8:45 AM EDT - 1 year ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Jun 16, 2025, 8:30 AM EDT - 1 year ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

May 31, 2025, 7:30 PM EDT - 1 year ago

Actuate Therapeutics Transcript: Study update

May 31, 2025, 7:30 PM EDT - 1 year ago

Actuate Therapeutics Press release: Study update

May 31, 2025, 4:30 PM EDT - 1 year ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

May 15, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Quarterly report: Q1 2025

Apr 23, 2025, 10:24 AM EDT - 1 year ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Proxy statement: Proxy filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Proxy statement: Proxy filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Registration statement: Registration filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Annual report: Q4 2024

Feb 6, 2025, 8:00 AM EST - 1 year ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Dec 17, 2024, 8:28 AM EST - 1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Nov 13, 2024, 7:00 AM EST - 1 year ago

Actuate Therapeutics Quarterly report: Q3 2024

Oct 29, 2024, 6:39 PM EDT - 1 year ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Quarterly report: Q2 2024

$Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma$

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 5, 2024, 9:10 AM EDT - 2 years ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 2 years ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

Mike_Rotsch Sep. 17 at 7:38 PM

$ACTU It doesn't like being under a dollar, does it?

0 · Reply

SamuraiX7 Sep. 11 at 11:01 PM

$ACTU $AEI $IMNN $SOAR $VSME VSME under big leg up coming

0 · Reply

Tonyto76 Sep. 11 at 3:07 PM

$ACTU WTF ? What's causing the dip ?

1 · Reply

prismmarketview Sep. 9 at 6:48 PM

0 · Reply

MaximusRadius Sep. 5 at 1:15 AM

$ACTU https://finance.yahoo.com/markets/stocks/articles/know-actuate-therapeutics-inc-actu-160002662.html

0 · Reply

MaximusRadius Sep. 4 at 6:09 PM

$ACTU 1.36 looks like support level

0 · Reply

MaximusRadius Sep. 4 at 3:58 PM

$ACTU building up steam for a nice run

0 · Reply

stockoptrader Aug. 26 at 6:35 PM

$ACTU interesting…

1 · Reply

StupidestTrader Aug. 26 at 6:27 PM

$ACTU needs to break and hold 2.00 if can test of 2.25 next, needs to hold if can 2.70... if 2.00 can't hold, look for 1.50, if that fails, 1.25

1 · Reply

SmartMoneyTradez Aug. 26 at 2:08 PM

$ACTU impending news? They are getting volume

0 · Reply

Tdth Aug. 25 at 6:44 AM

$ACTU chi..chizik nobody here?

1 · Reply

prismmarketview Aug. 20 at 8:47 PM

Risk-off Thursday across PRISM's indexes — just 5 of 27 finished higher. Crypto mining was the lone big winner, surging +10.07%, with sports (+2.26%), oil & gas (+1.43%) and precious metals (+0.60%) the only others in the green. The selling was broad — new energy (-3.51%), global health (-3.11%) and NextGen tech (-2.91%) led the declines. Biggest single-stock moves: $ACTU +16.04% and $BEEM +12.40% led the gainers, while $GWH -41.95%, $QTEX -24.88% and $CAPR -14.35% led the decliners. Full board below. Index detail at http://prismmarketview.com

0 · Reply

prismmarketview Aug. 20 at 4:33 PM

PRISM Mid-Day Movers: Sports and Crypto Mining are Today's Leaders. BTC Digital Ltd. (NASDAQ: $BTCT.X ) is sharply higher today, rising 83.98% to $1.5394, a gain of $0.7027 from its prior close of $0.8367. Mixed Martial Arts Group Limited (NYSE: $MMA ) is surging today, up 66.7% to $0.6397 after closing Wednesday at $0.3800. Other Notable Movers: Beam Global ( $BEEM) up 16% Actuate Therapeutics ( $ACTU) up 13% QTREX Quantum Ltd. ( $QTEX ) down -18% https://prismmarketview.com/prism-mid-day-movers-sports-and-crypto-mining-are-todays-leaders/ Stock prices and percentage changes are as of p.m. ET on August 20, 2026, and are subject to change.

0 · Reply

Mike_Rotsch Aug. 19 at 3:09 PM

$ACTU Why would you take a 100,000 share short entry here, of all places? Help me to understand.

0 · Reply

Mike_Rotsch Aug. 18 at 7:42 PM

$ACTU

0 · Reply

Mike_Rotsch Aug. 18 at 2:31 PM

$ACTU

1 · Reply

F14TOMCATIIAF Aug. 13 at 6:07 PM

$ACTU somebody there ?

0 · Reply

StockScanners Jul. 15 at 4:58 AM

$ACTU reached 1.95, easy money team

0 · Reply

StockScanners Jul. 15 at 4:13 AM

$ACTU kee pwatch if this holds above 1.67

0 · Reply

topstockalerts Jul. 14 at 8:23 PM

$ACTU not much noise, just consistent progress.

0 · Reply

PennySearch Jul. 14 at 7:00 PM

📈 Top Penny Stock Movers by Relative Volume $NXTC — 26.26x RVOL Move: +192% Volume: 104.7M (4.0M average) Market Cap: $17.1M Day Range: 5.76 – 9.90 52-Week Range: 1.55 – 15.74 $SHPH — 11.49x RVOL Move: +39% Volume: 51.7M (4.5M average) Market Cap: $2.4M Day Range: 3.81 – 5.09 52-Week Range: 2.71 – 55.90 $ACTU — 6.26x RVOL Move: +18% Volume: 2.4M (390.6K average) Market Cap: $42.3M Day Range: 1.53 – 1.90 52-Week Range: 1.16 – 9.22 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.

0 · Reply

Jacklin123 Jul. 14 at 6:59 PM

$ACTU power hour

0 · Reply

Market Cap	23.56M
Revenue (ttm)	0.00
Net Income (ttm)	-22.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	114,300
Avg Vol	410,544
Day's Range	N/A - N/A
Shares Out	24.01M
Stochastic %K	8%
Beta	0.95
Analysts	Strong Sell
Price Target	$9.20